NY AG sues Actavis over Alzheimer’s drug
New York's attorney general has launched an antitrust lawsuit against Actavis, accusing it of illegally trying to switch customers from a drug to treat Alzheimer’s disease, the patent on which expires soon, to a new drug in order to avoid competition from generic firms
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: